Myeloma statistics

Cases

New cases of myeloma, 2015, UK

Deaths

Deaths from myeloma, 2016, UK

Survival

Survive myeloma for 10 or more years, 2010-11, England and Wales

Prevention

Myeloma cases are preventable, UK, 2015

  • There are around 5,700 new myeloma cases in the UK every year, that's 15 every day (2013-2015).
  • Myeloma is the 19th most common cancer in the UK, accounting for 2% of all new cancer cases (2015).
  • In males in the UK, myeloma is the 16th most common cancer, with around 3,200 new cases in 2015.
  • In females in the UK, myeloma is the 19th most common cancer, with around 2,300 new cases in 2015.
  • Incidence rates for myeloma in the UK are highest in people aged 85 to 89 (2013-2015).
  • Since the early 1990s, myeloma incidence rates have increased by around a third (32%) in the UK. Rates in males have increased by more than a third (35%), and rates in females have increased by more than a fifth (22%).
  • Over the last decade, myeloma incidence rates have increased by a sixth (17%) in the UK. Rates in males have increased by around a sixth (18%), and rates in females have increased by around a seventh (14%).
  • Incidence rates for myeloma are projected to rise by 11% in the UK between 2014 and 2035, to 12 cases per 100,000 people by 2035.
  • 1 in 115 men and 1 in 155 women will be diagnosed with myeloma during their lifetime.
  • Myeloma in England is not associated with deprivation.
  • Myeloma is more common in Black people than in White and Asian people.
  • An estimated 17,600 people who had previously been diagnosed with myeloma were alive in the UK at the end of 2010.
  • In Europe, around 39,000 new cases of myeloma were estimated to have been diagnosed in 2012. The UK incidence rate is ninth highest in Europe for males and eight highest for females.
  • Worldwide, more than 114,000 new cases of myeloma were diagnosed in 2012, with incidence rates varying across the world.

See more in-depth myeloma incidence statistics

  • There are around 3,000 myeloma deaths in the UK every year, that's more than 8 every day (2014-2016).
  • Myeloma is the 17th most common cause of cancer death in the UK, accounting for 2% of all cancer deaths (2016).
  • In males in the UK, myeloma is the 16th most common cause of cancer death, with around 1,700 deaths in 2016.
  • In females in the UK, myeloma is the 16th most common cause of cancer death, with around 1,400 deaths in 2016.
  • Mortality rates for myeloma in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1970s, myeloma mortality rates have increased by three-fifths (60%) in the UK. Rates in males have increased by around seven-tenths (71%), and rates in females have increased by almost half (47%).
  • Over the last decade, myeloma mortality rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
  • Mortality rates for myeloma are projected to fall by 17% in the UK between 2014 and 2035, to 5 deaths per 100,000 people by 2035.
  • Myeloma in England is not associated with deprivation.
  • In Europe, around 24,300 people were estimated to have died from myeloma in 2012. The UK mortality rate is seventh highest in Europe for males and tenth highest for females.
  • Worldwide, around 80,000 people were estimated to have died from myeloma in 2012, with mortality rates varying across the world.

See more in-depth myeloma mortality statistics

  • A third (33%) of people diagnosed with myeloma in England and Wales survive their disease for ten years or more (2010-11).
  • Almost half (47%) of people diagnosed with myeloma in England and Wales survive their disease for five years or more (2010-11).
  • More than three-quarters (77%) of people diagnosed with myeloma in England and Wales survive their disease for one year or more (2010-11).
  • Myeloma survival is higher in men than women.
  • Around three quarters of people in England diagnosed with myeloma aged 15-49 survive their disease for five years or more, compared with a quarter of people diagnosed aged 80 and over (2009-2013).
  • Myeloma survival is improving and has quadrupled in the last 40 years in the UK.
  • In the 1970s, around 5 in 100 people diagnosed with myeloma survived their disease beyond ten years, now it's a third.

See more in-depth myeloma survival statistics

  • A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
  • 14% of myeloma cases in the UK are preventable.

See more in-depth myeloma risk factors

  • 'GP referral' is the most common route to diagnosing myeloma.
  • ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.
  • Around 7 in 10 patients with myeloma are treated with chemotherapy.

See more in-depth myeloma diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

The latest statistics available for myeloma in the UK are; incidence 2015, mortality 2016 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).

The ICD code Open a glossary item for myeloma (sometimes called multiple  myeloma) is ICD-10 C90.

European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.

Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.

Incidence data on the myeloma precursor condition monoclonal gammopathy of undetermined significance (MGUS) are also presented.

Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages, stages Open a glossary item and co-morbidities Open a glossary item. The survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics. If you are a patient, please see our patient information.

Meta-analyses Open a glossary item and systematic reviews Open a glossary item are cited where available, as they provide the best overview of all available research and most take study quality into account. Individual case-control and cohort studies Open a glossary item are reported where such aggregated data are lacking.

Overall, the evidence on myeloma risk factors is limited, mainly because of the relative rarity of this cancer type.

Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013.

Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Myeloma is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-cell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.

Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.

Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 3.4 out of 5 based on 36 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page